FDA Plays

[alexander77]

ZGNX: analyst target $6 tot $30

Zohydro will be the first opioid without any chance for liver toxity

Analysts at Stifel Nicolaus lowered their price target on shares of Zogenix (NASDAQ: ZGNX) to $6.00 in a research report issued to clients and investors on Thursday.

The analysts wrote, “We look to Zohydro to be the true value driver for Zogenix coming off another low quarter for Sumavel. Though the recent deal is dilutive, causing us to lower our target price to $6, Zogenix is in a better position for pipeline development, partner negotiations and eventual sales force investment.”

Separately, analysts at Oppenheimer reiterated an “outperform” rating on shares of Zogenix in a research note to investors on Thursday. They now have a $30.00 price target on the stock, up previously from $4.00.

http://www.i3investor.com/servlets/fdnews/76986.jsp